UnitedHealth Group (UNH) Price Target Lowered to $265.00 at Raymond James

UnitedHealth Group (NYSE:UNH) had its price target decreased by Raymond James from $310.00 to $265.00 in a research note released on Wednesday, April 17th, Stock Target Advisor reports. Raymond James currently has a strong-buy rating on the healthcare conglomerate’s stock.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded UnitedHealth Group from a hold rating to a buy rating and set a $279.00 target price on the stock in a report on Saturday, January 5th. SunTrust Banks reduced their target price on UnitedHealth Group to $300.00 and set a buy rating on the stock in a report on Wednesday, April 17th. They noted that the move was a valuation call. ValuEngine cut UnitedHealth Group from a buy rating to a hold rating in a report on Wednesday, February 27th. Oppenheimer lifted their target price on UnitedHealth Group from $300.00 to $305.00 and gave the company an outperform rating in a report on Wednesday, January 16th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $310.00 target price on shares of UnitedHealth Group in a report on Tuesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. UnitedHealth Group currently has a consensus rating of Buy and an average target price of $288.74.

Shares of NYSE:UNH opened at $237.97 on Wednesday. The firm has a market capitalization of $227.73 billion, a PE ratio of 18.48, a price-to-earnings-growth ratio of 1.24 and a beta of 0.74. The company has a quick ratio of 0.73, a current ratio of 0.73 and a debt-to-equity ratio of 0.63. UnitedHealth Group has a 52 week low of $208.07 and a 52 week high of $287.94.

UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings data on Tuesday, April 16th. The healthcare conglomerate reported $3.73 EPS for the quarter, beating the Zacks’ consensus estimate of $3.60 by $0.13. The business had revenue of $60.30 billion during the quarter, compared to the consensus estimate of $59.72 billion. UnitedHealth Group had a return on equity of 25.07% and a net margin of 5.45%. The business’s revenue for the quarter was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.04 earnings per share. On average, research analysts anticipate that UnitedHealth Group will post 14.7 earnings per share for the current fiscal year.

In related news, CEO David S. Wichmann acquired 20,000 shares of UnitedHealth Group stock in a transaction on Friday, May 3rd. The shares were bought at an average price of $231.79 per share, for a total transaction of $4,635,800.00. Following the completion of the purchase, the chief executive officer now directly owns 904,367 shares in the company, valued at approximately $209,623,226.93. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William C. Ballard, Jr. sold 5,000 shares of UnitedHealth Group stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $239.02, for a total value of $1,195,100.00. Following the sale, the director now directly owns 77,993 shares in the company, valued at $18,641,886.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,930 shares of company stock worth $6,746,683. 0.87% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the stock. Advisor Partners LLC increased its holdings in UnitedHealth Group by 6.5% in the fourth quarter. Advisor Partners LLC now owns 31,893 shares of the healthcare conglomerate’s stock valued at $7,945,000 after buying an additional 1,949 shares during the last quarter. TIAA CREF Investment Management LLC increased its holdings in UnitedHealth Group by 7.3% in the third quarter. TIAA CREF Investment Management LLC now owns 5,462,680 shares of the healthcare conglomerate’s stock valued at $1,453,291,000 after buying an additional 370,179 shares during the last quarter. Financial Enhancement Group LLC increased its holdings in UnitedHealth Group by 2,579.3% in the third quarter. Financial Enhancement Group LLC now owns 1,554 shares of the healthcare conglomerate’s stock valued at $413,000 after buying an additional 1,496 shares during the last quarter. Legacy Bridge LLC bought a new stake in UnitedHealth Group in the fourth quarter valued at about $824,000. Finally, LS Investment Advisors LLC increased its holdings in UnitedHealth Group by 38.9% in the fourth quarter. LS Investment Advisors LLC now owns 34,921 shares of the healthcare conglomerate’s stock valued at $8,700,000 after buying an additional 9,784 shares during the last quarter. 87.49% of the stock is owned by hedge funds and other institutional investors.

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Recommended Story: What do investors mean by earnings per share?

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.